1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
1 of 4
FEATURED COMPANIES
- AbbVie
- F. Hoffmann-La Roche
- Gilead
- Merck
- Sanofi
- MORE
Development of novel drugs to drive growth in the market. There has been an increase in the R&D of novel drugs for the treatment of infectious diseases. The analysts have predicted that the infectious disease therapeutics market will register a CAGR of over 4% by 2023.
Market Overview
Increasing prevalence of infectious diseases
There has been an increase in the prevalence of infectious diseases due to climate variability. This is expected to be a major driver of the market growth during the forecast period.
Availability of counterfeit drugs
Counterfeit drugs are available in low-income and developing countries. These drugs are widely available because of insufficient regulations and manufacturing control.
For the detailed list of factors that will drive and challenge the growth of the infectious disease therapeutics market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Merck and Sanofi, the competitive environment is quite intense. Factors such as the development of novel drugs and the increase in the prevalence of infectious diseases, will provide considerable growth opportunities to infectious disease therapeutics manufactures. AbbVie, F. Hoffmann-La Roche, Gilead, Merck, and Sanofi are some of the major companies covered in this report.
Market Overview
Increasing prevalence of infectious diseases
There has been an increase in the prevalence of infectious diseases due to climate variability. This is expected to be a major driver of the market growth during the forecast period.
Availability of counterfeit drugs
Counterfeit drugs are available in low-income and developing countries. These drugs are widely available because of insufficient regulations and manufacturing control.
For the detailed list of factors that will drive and challenge the growth of the infectious disease therapeutics market during the 2019-2023, view this report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Merck and Sanofi, the competitive environment is quite intense. Factors such as the development of novel drugs and the increase in the prevalence of infectious diseases, will provide considerable growth opportunities to infectious disease therapeutics manufactures. AbbVie, F. Hoffmann-La Roche, Gilead, Merck, and Sanofi are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- AbbVie
- F. Hoffmann-La Roche
- Gilead
- Merck
- Sanofi
- MORE
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 09: GEOGRAPHIC LANDSCAPE
Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Phase III pipeline drugs for infectious diseases
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Antiviral - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Antiviral - Year-over-year growth 2019-2023 (%)
Exhibit 23: Antibacterial - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Antibacterial - Year-over-year growth 2019-2023 (%)
Exhibit 25: Antifungal - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Antifungal - Year-over-year growth 2019-2023 (%)
Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Others - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by type
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 35: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 37: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Decision framework
Exhibit 42: Pipeline drugs for infectious diseases
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: AbbVie - Vendor overview
Exhibit 50: AbbVie - Business segments
Exhibit 51: AbbVie - Organizational developments
Exhibit 52: AbbVie - Geographic focus
Exhibit 53: AbbVie - Key offerings
Exhibit 54: F. Hoffmann-La Roche - Vendor overview
Exhibit 55: F. Hoffmann-La Roche - Business segments
Exhibit 56: F. Hoffmann-La Roche - Organizational developments
Exhibit 57: F. Hoffmann-La Roche - Geographic focus
Exhibit 58: F. Hoffmann-La Roche - Segment focus
Exhibit 59: F. Hoffmann-La Roche - Key offerings
Exhibit 60: Gilead - Vendor overview
Exhibit 61: Gilead - Business segments
Exhibit 62: Gilead - Organizational developments
Exhibit 63: Gilead - Geographic focus
Exhibit 64: Gilead - Segment focus
Exhibit 65: Gilead - Key offerings
Exhibit 66: Merck - Vendor overview
Exhibit 67: Merck - Business segments
Exhibit 68: Merck - Organizational developments
Exhibit 69: Merck - Geographic focus
Exhibit 70: Merck - Segment focus
Exhibit 71: Merck - Key offerings
Exhibit 72: Sanofi - Vendor overview
Exhibit 73: Sanofi - Business segments
Exhibit 74: Sanofi - Organizational developments
Exhibit 75: Sanofi - Geographic focus
Exhibit 76: Sanofi - Segment focus
Exhibit 77: Sanofi - Key offerings
Exhibit 78: Validation techniques employed for market sizing
Exhibit 79: List of abbreviations
PART 02: SCOPE OF THE REPORT
- Preface
- Currency conversion rates for US$
- Market ecosystem
- Market characteristics
- Market segmentation analysis
- Pipeline analysis
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
- Market segmentation by type
- Comparison by type
- Antiviral - Market size and forecast 2018-2023
- Antibacterial - Market size and forecast 2018-2023
- Antifungal - Market size and forecast 2018-2023
- Others - Market size and forecast 2018-2023
- Market opportunity by type
PART 09: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
- Market drivers
- Market challenges
- Market trends
- Overview
- Landscape disruption
- Vendors covered
- Vendor classification
- Market positioning of vendors
- AbbVie
- F. Hoffmann-La Roche
- Gilead
- Merck
- Sanofi
- Research methodology
- List of abbreviations
Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Phase III pipeline drugs for infectious diseases
Exhibit 07: Market definition - Inclusions and exclusions checklist
Exhibit 08: Market size 2018
Exhibit 09: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 10: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2018
Exhibit 19: Type - Market share 2018-2023 (%)
Exhibit 20: Comparison by type
Exhibit 21: Antiviral - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Antiviral - Year-over-year growth 2019-2023 (%)
Exhibit 23: Antibacterial - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Antibacterial - Year-over-year growth 2019-2023 (%)
Exhibit 25: Antifungal - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Antifungal - Year-over-year growth 2019-2023 (%)
Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Others - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by type
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 35: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 37: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Decision framework
Exhibit 42: Pipeline drugs for infectious diseases
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: AbbVie - Vendor overview
Exhibit 50: AbbVie - Business segments
Exhibit 51: AbbVie - Organizational developments
Exhibit 52: AbbVie - Geographic focus
Exhibit 53: AbbVie - Key offerings
Exhibit 54: F. Hoffmann-La Roche - Vendor overview
Exhibit 55: F. Hoffmann-La Roche - Business segments
Exhibit 56: F. Hoffmann-La Roche - Organizational developments
Exhibit 57: F. Hoffmann-La Roche - Geographic focus
Exhibit 58: F. Hoffmann-La Roche - Segment focus
Exhibit 59: F. Hoffmann-La Roche - Key offerings
Exhibit 60: Gilead - Vendor overview
Exhibit 61: Gilead - Business segments
Exhibit 62: Gilead - Organizational developments
Exhibit 63: Gilead - Geographic focus
Exhibit 64: Gilead - Segment focus
Exhibit 65: Gilead - Key offerings
Exhibit 66: Merck - Vendor overview
Exhibit 67: Merck - Business segments
Exhibit 68: Merck - Organizational developments
Exhibit 69: Merck - Geographic focus
Exhibit 70: Merck - Segment focus
Exhibit 71: Merck - Key offerings
Exhibit 72: Sanofi - Vendor overview
Exhibit 73: Sanofi - Business segments
Exhibit 74: Sanofi - Organizational developments
Exhibit 75: Sanofi - Geographic focus
Exhibit 76: Sanofi - Segment focus
Exhibit 77: Sanofi - Key offerings
Exhibit 78: Validation techniques employed for market sizing
Exhibit 79: List of abbreviations
Note: Product cover images may vary from those shown
3 of 4
LOADING...
4 of 4
FEATURED COMPANIES
- AbbVie
- F. Hoffmann-La Roche
- Gilead
- Merck
- Sanofi
- MORE
Global Infectious Disease Therapeutics Market 2019-2023
The analyst recognizes the following companies as the key players in the global infectious disease therapeutics market: AbbVie, F. Hoffmann-La Roche, Gilead, Merck, and Sanofi.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of novel drugs.”
According to the report, one of the major drivers for this market is the increase in the prevalence of infectious diseases.
Further, the report states that one of the major factors hindering the growth of this market is the availability of counterfeit drugs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
The analyst recognizes the following companies as the key players in the global infectious disease therapeutics market: AbbVie, F. Hoffmann-La Roche, Gilead, Merck, and Sanofi.
Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the development of novel drugs.”
According to the report, one of the major drivers for this market is the increase in the prevalence of infectious diseases.
Further, the report states that one of the major factors hindering the growth of this market is the availability of counterfeit drugs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
- AbbVie
- F. Hoffmann-La Roche
- Gilead
- Merck
- Sanofi
Note: Product cover images may vary from those shown
![[CF] Infectious Disease - Disease & Epidemiology Overview - Product Image](http://d386vep05x5edh.cloudfront.net/product_images/7972/7972673_60px_jpg/infectious_disease_disease_and_epidemiology_overview.jpg)
![[CF] Bacteremia - Pipeline Insight, 2019 - Product Image](http://d386vep05x5edh.cloudfront.net/product_images/8015/8015481_60px_jpg/bacteremia_pipeline_insight_2019.jpg)
![[CF] Plague - Pipeline Review, H1 2019 - Product Image](http://d386vep05x5edh.cloudfront.net/product_images/8021/8021849_60px_jpg/plague_pipeline_review_h1_2019.jpg)
![[MLT] Global Hepatitis C Drugs Market 2019-2023 - Product Image](http://d386vep05x5edh.cloudfront.net/product_images/8018/8018165_60px_jpg/global_hepatitis_c_drugs_market_20192023.jpg)
![[MLT] Global Antiviral Drugs Market 2017-2021 - Product Image](http://d386vep05x5edh.cloudfront.net/product_images/5039/5039564_60px_jpg/global_antiviral_drugs_market_20172021.jpg)